Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4836695 | 0.82 | POLB (0.51) | TSHRLMNAALDH1A1POLBRIPK1 | |
| SCHEMBL8773928 | 0.78 | CRHBP (0.39) | LMNAALDH1A1HTTRIPK1MEN1 | |
| SCHEMBL8773924 | 0.78 | CRHBP (0.39) | LMNAALDH1A1HTTRIPK1MEN1 | |
| SCHEMBL10918542 | 0.78 | TSHR (0.71) | TSHRCYP19A1LMNAALDH1A1HTT | |
| SCHEMBL8824655 | 0.77 | MAPT (0.52) | TSHRALDH1A1POLBMEN1MAPT | |
| SCHEMBL8534580 | 0.76 | GAA (0.43) | ALDH1A1HTTPOLBMEN1MAPT | |
| SCHEMBL9911071 | 0.75 | DAO (0.43) | ALDH1A1POLBKDM4ETDP1 | |
| SCHEMBL31422574 | 0.75 | DAO (0.31) | — | |
| SCHEMBL17911903 | 0.74 | TAAR1 (0.55) | TSHRADORA2ACYP19A1LMNAALDH1A1 | |
| SCHEMBL10965025 | 0.74 | TSHR (0.34) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | WEIGAND KLAUS | 2008-12-11 | — | — | US | disclosed |
| CN-101296911-A | Arylurea derivatives as modulators of chemokine receptor activity | NOVARTIS AG (CH) | 2008-10-29 | — | — | CN | disclosed |
| EP-1943235-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Novartis AG (CH) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007048771-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2007-05-03 | — | — | WO | disclosed |
| US-5763437-A | Benzodiazepine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-09 | — | — | US | disclosed |
| EP-0804425-A2 | BENZODIAZEPINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996004254-A2 | BENZODIAZEPINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-02-15 | — | — | WO | disclosed |
| US-5475106-A | Agonist for cholecystokinin and gastrin receptors; nervous system, gastrointestinal disorders | RHONE-POULENC RORER S.A. (FR) | 1995-12-12 | — | — | US | disclosed |
| US-5382590-A | Gastrointestinal disorders and nervous system disorders | RHONE-POULENC RORER S.A. (FR) | 1995-01-17 | — | — | US | disclosed |
| CN-1074216-A | Urea derivative | GLAXO GROUP LTD (GB) | 1993-07-14 | — | — | CN | disclosed |
| WO-1993008175-A1 | BENZODIAZEPINE DERIVATIVES AS ANTAGONISTS OF GASTRIN AND/OR CHOLECYSTOKININ | GLAXO GROUP LIMITED (GB) | 1993-04-29 | — | — | WO | disclosed |
| EP-0538945-A1 | Benzodiazepine derivatives, and their use as antagonists of gastrin and/or cholecystokinin | GLAXO GROUP LIMITED (GB) | 1993-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | CCR3, CCR1, CCR4 | TSHR 1110/4885ADORA2A 678/4885CYP19A1 3315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.